Find us @

Feature

Novavax applies to have emergency supplemental authorization of its COVID-19 booster

The number of people who haven’t received their first shot has reached 110 million.

Published

on

According to the firm, Novavax has applied to the Food and Drug Administration for emergency use authorization of its COVID-19 vaccine as a booster in adults that can be combined with other primary vaccine series or used in addition to its primary vaccine series.

According to Stanley C. Erck, president and chief executive officer of Novavax, “it’s crucial for people to have a choice as they consider how to keep protected against COVID-19, and boosters are an invaluable tool to build upon immunity established from past vaccines.”

Erck stated, “We believe our vaccine offers a wide, long-lasting immune response against a spectrum of variations based on the data given to the FDA’s VRBPAC and the CDC ACIP.

Only 9,700 doses of Novavax’s COVID-19 vaccine have been delivered nationwide, despite the fact that half a million doses of the company’s vaccine have now been distributed to states following its approval last month.

The vaccines were not immediately made available after authorization, which may have contributed to the slow start and caused some reporting delays.

The COVID-19 vaccine from Novavax was approved for use last month by representatives of the Centers for Disease Control and Prevention, making it the fourth COVID-19 vaccine to be made available to the American public.

The COVID-19 vaccine from Novavax was acquired by the Biden administration in 3.2 million doses.

The Novavax vaccine is based on a more conventional protein-based technology that is already used for the flu vaccine and other shots, whereas Pfizer and Moderna vaccine platforms tapped a new genetic technology — with messenger RNA — to produce their vaccines. As a result, some of the people who are still reluctant to get shots may be more likely to get the Novavax vaccine.

Early signs indicate that the authorisation has not yet persuaded a sizable portion of the 26 million adult Americans who are unvaccinated to get the vaccination.

Although overall adoption may still be low, certain Americans who have received the COVID-19 vaccines from Moderna, Pfizer, or Johnson & Johnson may be more motivated to receive the booster from Novavax, according to experts.

“Having vaccine alternatives will probably help to increase immunization rates. This increase in vaccine uptake may be somewhat limited given that so many Americans have not yet received their booster shots despite the fact that there is strong evidence to support their effectiveness in lowering the risk of serious COVID-19 complications “said epidemiologist at Boston Children’s Hospital and ABC News contributor John Brownstein, Ph.D.

According to data from the CDC, 110 million Americans nationwide — or more than half of those who are eligible to be boosted — have not yet had their first booster shot.

In a similar vein, only a third of the nearly 61 million adults over 50 who are eligible to receive their second COVID-19 booster dose have actually done so.